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INTRODUCTION
Angiogenesis, the formation of new blood vessels from the endothelium of pre-existing vasculature, plays a central role in tumor growth and metastasis [1] .
Once a tumor grows beyond 1-2 mm in size, passive diffusion of nutrients and oxygen is insufficient and neovascularization becomes necessary [2] . These newly formed blood vessels are highly abnormal and heterogeneous, even in tumors of equal histology and grade [3] [4] [5] . Areas of dilated, tortuous, and leaky vessels exist together with less abnormal areas [6, 7] . Interstitial hypertension, caused by vascular hyperpermeability and mechanical stress of lymphatics by tumor cell growth, can lead to blood flow stasis or even retrograde flow in tumors [8, 9] . This results in hypoxia and acidosis, which in turn is a major cause of resistance to radiation and chemotherapy and associated with a poorer prognosis [10] .
Recently, drugs have been designed to specifically inhibit angiogenesis. Their effect typically results in consolidation of the tumor mass instead of regression.
Therefore, the standard volumetric approach with computed tomography (CT) (Response Evaluation Criteria in Solid Tumors) may not be sufficient to assess treatment response. Measuring change in tumor blood flow (perfusion) during antiangiogenic therapy might allow for the discrimination of responders from nonresponders irrespective of volumetric response.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography using radiolabeled water (H 2 15 O-PET) are sensitive techniques that aim to noninvasively study and quantify the physiology of tumor microcirculation. Both techniques are based on the continuous acquisition of two-dimensional (2D) or 3D images during the uptake and clearance of an administered tracer. DCE-MRI makes use of paramagnetic tracers, mostly consisting of a low-molecular-weight gadolinium (Gd)-based agent. PET uses positron-emitting tracers, of which H 2 15 O can be used to study tumor blood flow. Both techniques are now being used in several phase I, II, and III clinical trials evaluating tumor vascular response to antiangiogenic drugs. However, acquisition protocols and study designs are far from uniform and may affect results. This complicates the comparison of imaging studies and possibly results in an underestimation of the abilities of DCE-MRI and H 2 15 O-PET. Both PET and MRI have specific advantages and disadvantages. Some limitations are inherent to the techniques, but others can be overcome by study design. These issues need to be addressed when designing a study and must be kept in mind when interpreting the results of such studies.
Mutual understanding between those using H 2 15 O-PET and those using DCE-MRI in oncology is generally very limited. Both techniques have great potential, but limitations still exist and must not be neglected. This is the first review to discuss both H 2 15 O-PET and DCE-MRI in monitoring tumor vascular response side-by-side. We focus on the technical and physiological aspects of both techniques and aim to supply the reader with essential information necessary to critically evaluate the use of DCE-MRI and H 2 15 O-PET in an oncological setting. First, the technical and physiological background of PET and MRI are discussed. Then, the methodology of flow measurements with both techniques is presented, and their validation and reproducibility are addressed. Finally, the application of DCE-MRI and H 2 15 O-PET in monitoring response to anticancer treatment and the methodological considerations influencing quantitative measurements of tumor perfusion are discussed.
BLOOD FLOW MEASUREMENTS Background

Technical Background of PET/MRI Signal
There is a fundamental difference between imaging an MRI contrast agent and imaging a PET tracer. Paramagnetic contrast agents are not by themselves detectable with MRI, but are visible because they shorten T1 and T2 relaxation times of the nearby hydrogen nuclei. In clinical practice, Gd compounds are most commonly used. The relation between signal intensity and Gd concentration is complicated. Gd concentration cannot be measured directly, because the signal enhancement (T1 relaxation) is a characteristic of the tissue being studied. There is no linear relationship between the degree of enhancement and the Gd concentration, particularly at high concentrations. Therefore, absolute quantification with DCE-MRI is difficult, and most often the proportional change in signal enhancement between the baseline and post-treatment measurements is used.
In contrast, H 2 15 O concentration shows a linear relation with signal intensity as measured with PET. Therefore, this technique is able to absolutely quantify tumor perfusion. H 2 15 O is a freely diffusible positron-emitting tracer. Therefore, regional uptake directly and specifically reflects tissue perfusion. Gd-based contrast agents are never freely diffusible. Therefore, the degree of signal enhancement with DCE-MRI depends on several physiological and physical characteristics, including contrast concentration, tissue perfusion, permeability, and volume of the extracellular extravascular space (EES) [11] . Thus, H 2 15 O-PET and DCE-MRI are both able to monitor tumor microvasculature, but the first specifically measures tissue perfusion whereas the latter measures a combination of processes, mainly perfusion and permeability.
Physiological Background of PET/MRI Signal
Modeling Signal Intensity
General Model PET and DCE-MRI perfusion measurements are both based on the Fick principle (Fick, 1870) and analyzed according to the Kety-Schmidt model [12] , although the nomenclatures used in PET and DCE-MRI are slightly different. In a dynamic scan, dC tissue (t)/dt (the change in tissue concentration of a flow tracer or contrast agent at a certain time point) is equal to K 1 (the plasma to tissue transport rate constant) times C plasma (t) (the tracer concentration) minus k 2 (the tissue to plasma rate constant) times the tracer concentration in tissue at that point in time:
The compartment model corresponding to this equation is shown in Figure 1 . K 1 equals flow F multiplied by extraction fraction E, which in its turn is a function of F and the permeability surface product PS (the latter only being relevant in the case of nonfreely diffusible tracers):
In H 2 15 O-PET studies, K 1 is equal to F and thus represents true blood flow, whereas in DCE-MRI studies, K 1 is a function of blood flow (F), permeability (P), and the vascular surface (S) and is also called K trans or K ps . The term K trans is generally used to describe the kinetics of contrast agents with a high PS product, thus mainly representing perfusion, whereas K ps is used for contrast agents with a lower PS product and thus represents a mixed effect of perfusion and permeability as shown in equation 2 [13, 14] .
With H 2 15 O-PET, C plasma is effectively equal to C blood because of the rapid exchange between blood cells and plasma. With DCE-MRI, C plasma is calculated as C blood divided by one minus the hematocrit, because Gd contrast agents are only present in plasma. For both techniques, a large vessel within the imaged volume can be used for definition of an image-derived arterial input function (IDIF). In order to use an IDIF, a feeding input vessel of substantial size (such as the aorta or left ventricle) must be included in the imaged volume, together with the target lesion. With PET, C blood or the arterial input function (AIF) can be measured using (continuous) arterial blood sampling during the scan.
For a freely diffusible tracer with 100% extraction, such as water in the range of flow values relevant for tumor imaging, equation 1 corresponds to:
Here, V T is the tissue to plasma concentration ratio in equilibrium, which corresponds to the partition coefficient of water. V T is equal to one if there is full exchange of tracer between blood and tissue. The solution of this equation, including a fractional blood volume v b , is:
A nonlinear least-squares fit of this function to the measured time-activity curve in the tissue of interest yields the perfusion F and distribution volume of water V T [15] . Therefore, this method also allows for the quantification of tissue perfusion when V T does not equal one.
In the case of MRI, a different nomenclature is used. Low-molecular-weight Gd is not freely diffusible, but partially leaks through the vessel wall into the interstitial space and leaks more through pathological tumor vessels as a result of greater permeability. DCE-MRI applying Gd contrast agents exploits this hyperpermeable nature of tumor vessels. The same kinetic model as above can be applied to fit DCE-MRI data [16] . Tofts et al. [11] proposed the terms K trans , k ep , fPV, and v e as outcome parameters derived from this single-tissue compartment model. The equation is similar to equation 3: This equation describes the change in contrast agent concentration in the interstitium of the tumor tissue C tissue (t), where C plasma (t) is the concentration of contrast agent in the plasma space of the tumor tissue. K trans is the endothelial transfer coefficient surface area product, which is the transport rate constant from plasma to tumor tissue. k ep is the reflux coefficient or the transfer of contrast agent from tissue back to the blood. The solution of this equation is similar to the solution given for PET:
The two compartments within the tumor are the blood plasma and the EES. fPV is the fraction of plasma volume related to whole tissue volume. v e , which equals K trans /k ep , is a measure for the EES fraction. Note that the definitions of F and K trans , and V T and v e , are not similar because water is freely diffused in tissue, including cells, whereas Gd is only transferred into the extracellular space. Table 1 lists all the parameters involved in modeling PET and MRI signaling.
Specific Aspects of H 2
15 O-PET A dynamic PET scan following a bolus injection of H 2 15 O consists of a series of consecutive short scans (frames), with typical durations starting with 5 seconds per frame and increasing to 30 seconds per frame (totaling 10 minutes), and starts simultaneously with the bolus injection. Although frame durations shorter than 5 seconds are possible, they would result in very noisy images because of the low number of counts per frame and this would not contribute to more reliable flow measurements. The amount of injected H 2 15 O is about 1 GBq and depends on the high count rate capabilities of the scanner. Prior to the emission scan, a short (several minutes) transmission scan using rotating 68 Ge rod sources, analogous to a CT scan but acquired with 511 keV gamma radiation instead of xrays, has to be performed to correct for photon attenuation in tissue. In the case of combined PET-CT scanners, a low-dose (20 -50 mAs) CT scan can be used for this purpose. A conventional PET scan after administration of 1 GBq H 2 15 O results in an effective radiation dose of approximately 1 mSv, or about half the average annual radiation load per person from the environment [17] . A combined PET-CT scan with 500 MBq H 2 15 O and a 30-mAs low-dose CT of, for example, the thorax results in a higher effective dose of 1.4 mSv. In the latter case, the lower amount of administered H 2 15 O is feasible because of the improved signal-to-noise ratio of state-of-the-art scanners. The spatial resolution of PET images is on the order of 6 mm in all three directions in clinical PET scanners. Because of the short radioactive half-life of 15 O (2 minutes), a scan can be repeated within 10 minutes of the previous scan, which allows for the measurement of direct short-term therapy effects within one imaging session. Also, a scan can be followed by a second scan with a different tracer to study other aspects of tumor biology. Because of the short half-life, H 2 15 O-PET studies require the availability of an on-site cyclotron for the production of 15 O. 
Specific Aspects of DCE-MRI
For DCE-MRI, a clinical MRI scanner can be used with field strength usually in the range of 1-3 Tesla. The scanning protocol starts with high-resolution 3D imaging of the tumor and its environment, with both T1-and T2-weighted sequences. These images are used to delineate the tumor volume. The protocol continues with five precontrast T1-weighted measurements with different flip angles to determine the T1 relaxation time in the blood and tissue before contrast arrival. This T1 value is required for the modelbased quantification [16] . Then, the contrast is given by i.v. injection. Upon injection, the dynamic acquisition starts using the same 3D T1-weighted pulse sequence and the same slice positions, but with a fixed flip angle (e.g., 35 degrees), containing 30 -35 scans of about 1 second each. Thus, the temporal resolution is 1 second. The spatial resolution inplane is about 1.5 ϫ 1.5 mm, and through-plane is about 10 mm. The use of thick image planes, however, leads to a degradation of in-plane resolution, depending on heterogeneity in the axial direction, because each plane represents an average image of a 10-mm thick volume. For all tumors that are subject to respiratory motion, the patient is asked to hold his breath as long as possible. Renal clearance of contrast occurs with an elimination phase half-life of 100 minutes [18] . Because of the relatively slow clearance of contrast agent, DCE-MRI scans cannot be repeated within the same imaging session. Figure 2 shows images of a dynamic MR sequence following a contrast bolus injection. Despite the many research papers in this field, consensus is lacking on the exact kinetic model to be used for DCE-MRI. Therefore, model-free quantification of DCE-MRI data is still widely applied. This approach calculates basic properties of the tissue enhancement curve, such as time to onset and peak and end, time intervals of rising and transit, amplitude, and the mean and maximum upslope of the DCE-MRI tissue enhancement curve. The upslope values can be normalized for the area-under-the-curve and upslope of the AIF. Another frequently used semiquantitative measurement is the initial area under the Gd concentration curve (AUGC).
Parametric Images
In principle, it is possible to apply the above equations on a pixel-by-pixel basis to obtain parametric images, a graphical representation showing F, V T, K trans , or v e , for each pixel [19] . Parametric images retain the original image resolution, allowing for better assessment of heterogeneity than region of interest (ROI)-based methods. Heterogeneity analyses can add to ROI analyses, and DCE-MRI seems especially promising because of its high spatial and temporal resolution. Nonlinear least-squares fitting of equations 4 or 6 on a pixel-by-pixel basis is very time-consuming, which is not a limiting factor for MRI because of the small number of image planes, but is impractical for the number of voxels of about one million in a typical clinical PET image volume. In addition, it yields noisy parametric images. Although a subregion of the total imaged volume can be selected in order to limit the computation time, faster methods are available and preferable. Basically, there are two fast options for creating parametric images. First, the differential equation 1 can be integrated on both sides, resulting in the following equation: Representative dynamic contrast-enhanced magnetic resonance images from a patient with non-small cell lung cancer. The sequential images show the tumor at different time points after contrast bolus administration. The signal intensity curve over time was measured in the tumor, the aorta, and the pulmonary artery (AP).
When evaluating this equation and plotting, for each frame, the left-hand side of the equation versus the integral ratio on the right-hand part, this equation describes a straight line, intercepting the y-axis at K 1 (F or K trans ) and the x-axis at K 1 /k 2 (V T or v e ). Using this linearization, F and V T (or K trans and v e ) can be obtained for each pixel using a simple and fast linear least-squares fit [20] .
The second option to create parametric images is by the use of basis functions:
A set of basis functions exp(Ϫ␤ i t) R C plasma (t) is created by convolution of the plasma input function with a set of single exponential functions, with exponential clearance rate constants ␤ i , for example, between 0.01 and 1 min Ϫ1 . For each voxel, the basis function that, multiplied by K 1 (F or K trans ), best fits the measured data is selected. Each of these iterations involves a simple linear fit procedure, which is much faster than a nonlinear fit and limits the time necessary to construct parametric images from several hours to several minutes. In addition, this method reduces image noise while allowing for inclusion of a blood volume compartment and retaining the quantitative accuracy of the resulting parametric images. The basis function method also allows for fixation of V T or v e to further reduce noise [19, 21] . and myocardium [22] [23] [24] [25] [26] [27] . Some validation studies have been performed in other tissues, including the lung [28, 29] , kidney [30] , and skeletal muscle [31, 32] . To date, no validation studies have been performed in tumors. In theory, the model should also fit tumor perfusion measurements because H 2 15 O is freely diffusible throughout the body and the range of reported values (0.15-1.29 ml blood/ml tissue per minute) lies well within the range of validated perfusion values [33, 34] . On the other hand, typical vascular abnormalities in tumor tissue (vascular shunts, large vessels situated within a lesion) can result in overestimation of perfusion if models are used without correction for these effects [35, 36] . Therefore, validation studies in tumors are still needed and awaited. 
Reproducibility
In brain and myocardium [37] [38] [39] [40] , as well as in some other tissues [34, 41, 42] , H 2 15 O-PET has been shown to be reproducible with within-subject coefficients of variation (wCV) in the range of 9%-14%. The reproducibility value (defined as the range within which 95% of measurements fall) was in the range of 22%-34%. Two oncological studies have been performed [15, 34] . Although the study groups were small, reproducibility results were in the same range as those observed in the brain and myocardium, with wCV of 11% for abdominal tumors [34] and errors up to 10% reported for breast tumors [15] .
DCE-MRI
Validation
The first approach for validating DCE-MRI perfusion is to verify whether an MRI-derived parameter does indeed deliver absolute perfusion measurements. No such validation study has been performed in tumors. In the human myocardium, K trans was compared with myocardial perfusion as measured using H 2 15 O-PET [43] . There was a strong correlation for dipyridamole-induced flow (r ϭ 0.70; p ϭ .001) and a moderate correlation for myocardial perfusion reserve (r ϭ 0.48; p ϭ .04) between MRI and PET. In a second approach, it was validated against immunohistochemistry as the gold standard. Correlation of DCE-MRI signal enhancement with microvascular density (MVD) was found to be inconsistent [44] . One reason for this may be that tissue enhancement is not only determined by MVD but also by the status of the capillary-interstitial space barrier (vessel wall permeability), which is not accounted for by immunohistochemistry. In breast cancer lesions, tissue expression of vascular endothelial growth factor (VEGF) was closely correlated to k ep [45] . Because VEGF expression shows a spatial association with vessel permeability [46, 47] , this finding further supports the theory that enhancement of the DCE-MRI signal partially reflects vessel permeability.
Because DCE-MRI measures a combination of flow and permeability, it is difficult to validate. Attempts have shown that signal enhancement reflects vascular status, but validation studies in tumors, as have been done for the myocardium, are still awaited.
Reproducibility
Two studies have evaluated reproducibility in an oncological setting. The first evaluated the reproducibility of quantitative and semiquantitative kinetic parameters in 21 patients with solid tumors [48] . AUGC and v e were found to be reproducible with wCVs of 12% and 9%, respectively. K trans and k ep showed greater variability (with wCVs of 29% and 24%, respectively). The latter are more sensitive to changes in the AIF, which could explain the lower reproducibility. Comparable results were found in a study of 11 patients with advanced cancers [49] . AUGC and K trans showed wCVs of 16% and 19%, respectively. The reproducibility value was 30% for AUGC and 36% for K trans . With serial imaging of patients, a decrease in K trans of Ͼ40%-45% can be addressed as a treatment effect [48 -51] .
MONITORING RESPONSE TO ANTICANCER TREATMENT
Predicting response to therapy as early as possible creates the opportunity to customize patient treatment. There is a need for this "customization" because response rates to intensive treatment with serious, and sometimes lethal, side effects are often low. To continue treatment with limited or no effect only provides the patient with side effects, while depriving the patient of potential benefit from other treatment. The ultimate goal is to customize treatment prior to initiation. Encouraging results have been published on gene-expression profiling, where correlations between gene expression and drug sensitivity were found [52] [53] [54] . Some success has been achieved in measuring the expression level of tumor markers to which the drug is targeted [55] . However, before these tools can be used in a clinical setting, further research is needed. Until then, predicting response early in treatment is still a major step forward when compared with size-based response evaluation after several cycles of systemic therapy.
MONITORING RESPONSE TO ANTIANGIOGENIC THERAPY
Several components of tumor vasculature have been targeted by systemic drugs. The main differentiation can be made between antiangiogenic and antivascular drugs. The first inhibit neovascularization. The most striking inhibition has been accomplished by targeting VEGF, via either monoclonal antibodies (MAbs) directed against circulating VEGF or by targeting the VEGF receptor (VEGFR) with tyrosine kinase inhibitors (TKIs). Bevacizumab (a VEGF MAb) has been shown to decrease tumor perfusion, vascular permeability, MVD, interstitial fluid pressure (IFP), and circulating endothelial and progenitor cells [56] . This suggests a direct antivascular effect. Receptor TKIs generally target not only the tyrosine kinase of the VEGFR but also the tyrosine kinases of other receptors, such as the plateletderived growth factor receptor, fibroblast growth factor receptor, and epidermal growth factor receptor (EGFR), which suggests additional effects when compared with MAbs. Examples are imatinib, sorafenib, and sunitinib. Selective blocking of EGFR is another inhibitory pathway of angiogenesis [57] . Examples of EGFR TKIs are erlotinib and gefitinib. Antivascular or vascular disruptive agents (VDAs) damage existing blood vessels, aiming at depriving the tumor from oxygen and nutrients. Combretastatin, the major VDA under investigation, is able to rapidly shut down blood vessels and can result in pronounced tumor necrosis in patients with solid tumors [58, 59] .
Knowledge of the nature of a drug action, and its influence on PET and MRI derived parameters, can aid in choosing the best imaging tool and time interval to monitor response. H 2 15 O-PET measures perfusion and V T . Because water is freely diffusible, a change in vascular permeability cannot be monitored accurately, although this could be measured with PET using other tracers such as [
68 Ga]transferrin or [ 11 C]methylalbumin [23, 60] . A decrease in IFP (resulting from a decrease in vascular permeability or lowering of mechanical stress by reducing tumor cell density) results in an increase in perfusion. A decrease in MVD results in a decrease in perfusion. V T (the ratio of H 2 15 O in tissue to that in plasma at equilibrium) is expected to be stable with antiangiogenic therapy and to decrease with antivascular therapy because of induced necrosis or increased intercapillary distance.
DCE-MRI-derived K trans has several physiological interpretations, depending on the balance between capillary permeability and blood flow. In situations in which capillary permeability is very high, the flux of contrast agent into the EES is flow limited and K trans will approximate tissue perfusion. On the other hand, when permeability is low and blood flow is high, K trans gives an indication of capillary permeability. However K trans frequently indicates a combination of flow and capillary permeability [11] . A decrease in vascular permeability and/or MVD results in a decrease in K trans because of a lower extraction rate and lower blood vessel surface area, respectively. A decrease in IFP, however, results in an increase in K trans because of lower interstitial resistance.
As indicated, antiangiogenic therapy promotes several morphological and functional changes in a tumor with sometimes opposite effects on MRI-and PET-derived parameters. The net effect is measured, and therefore it is of no surprise that the relation between treatment effects and imaging parameters is not straightforward. showed a decrease in one patient with stable disease, an increase in one with progressive disease, and no change in three patients [61] . Razoxane (a cytostatic and antiangiogenic agent) was shown to reduce tumor perfusion in patients with advanced renal cell cancer [62] . Statistical significance, however, was not reached, and perfusion did not correlate with tumor progression, possibly because of the small sample size. Response monitoring to endostatin and combretastatin therapy revealed a reduction in tumor perfusion, as measured with H 2 15 O-PET [59, 63] . Both studies showed a dose-dependent reduction in perfusion, with a nonlinear relation in the endostatin study. Combretastatin caused a rapid perfusion reduction in solid tumors after 30 minutes, which remained significant after 24 hours. Interestingly V T also was determined, which showed a reduction 30 minutes after injection with recovery after 24 hours. This trend might be a result of partial reversal of the vascular response, indicating that part of the tissue was targeted but still viable.
DCE-MRI has been incorporated into several phase I and II trials. PTK/ZK (a VEGFR TKI) has been tested in a phase I trial in patients with advanced cancers [50, 51, 64] . DCE-MRI was performed at baseline, day 2, and the end of each 28-day cycle. K trans decreased in a dose-dependent way. A reduction of Ͼ40% in the baseline value at day 2 was predictive of stable disease. In a recent phase II study, patients with advanced breast cancer were treated with bevacizumab monotherapy for one cycle, followed by six cycles of bevacizumab, doxorubicin, and docetaxel. Significant reductions in K trans , k ep , and v e were seen after one cycle, which persisted when cytotoxic chemotherapy was added. The decreases in K trans , k ep , and v e were correlated with increased apoptosis and a reduction in VEGFR expression [65] . Several targeted agents have been shown to decrease DCE-MRI-derived parameters in a dose-dependent manner, making DCE-MRI a useful indicator in drug pharmacology [66, 67] . A recent study of DCE-MRI in patients with progressive multiple myeloma treated with thalidomide found amplitude A, which is proportional to the relative signal enhancement, to be a good prognostic indicator of progression-free survival [68] .
Most PET and MRI results are derived from small studies. Together with heterogeneity in acquisition protocols and study design, these factors might limit their value. Therefore, prospective phase III trials with predefined cutoff values for PET and MRI results are awaited. 
Potential Synergistic Value of DCE-MRI and
Combining Information on Tumor Vasculature and Metabolism
Tumor metabolism can be measured with 18 FDG-PET. 18 FDG uptake is the product of perfusion and extraction. It can be hypothesized that poorly perfused and hypometabolic areas reflect necrosis, while poorly perfused and hypermetabolic areas reflect hypoxia (because of anaerobic glucose hypermetabolism under hypoxic circumstances). It is possible to measure oxygen consumption directly using 15 O 2 and PET. Knowledge of the regional tumor microenvironment can supply relevant information on mechanisms of treatment failure, but can also aid in treatment planning (e.g., radiotherapy). Recently, the synergistic value of H 2 15 O-PET and 18 FDG-PET was shown in breast cancer, where a pretherapeutic low ratio of 18 FDG uptake to perfusion was the best predictor of complete response to neoadjuvant chemotherapy and also predictive of disease-free survival [69] . 18 FDG metabolism and perfusion were positively correlated, although highly variable. Zasadny et al. [70] also found a positive correlation between 18 FDG metabolism and perfusion, with the additional finding of a higher slope of the curve at lower flow rates, possibly indicating hypoxia in areas with low perfusion and high metabolism. In contrast, 18 FDG metabolism was found to be negatively correlated with perfusion in non-small cell lung cancer (NSCLC), liver tumors, and head and neck cancer. Perfusion in the latter two was assessed with contrastenhanced CT [71] [72] [73] . In NSCLC and head and neck cancer, the ratio was found to positively correlate with tumor size, suggesting the presence of hypoxia in larger tumors where tumor growth exceeds angiogenesis [71, 73] . In contrast, a high tumor perfusion rate predicted poor response to radiotherapy in head and neck cancer [74] . This reflects the complexity of tumor biology. High tumor blood flow does not immediately indicate sufficient oxygenation and thus favorable radiotherapy outcome. Hypoxia stimulates angiogenesis via upregulation of specific transcription and growth factors, like VEGF [75] . This results in a more complex, but abnormal, chaotic vascular network with increased blood flow, but inadequate oxygen and nutrient supply. Thus, hypoxic areas can exist irrespective of high blood flow, a finding confirmed in a PET study in brain tumors using fluorine-18 fluoromisonidazole (a hypoxia tracer) and H 2 15 O [76] .
Timing of Response Evaluation
Jain [77, 78] introduced the term "normalization" to describe the (transient) reversal of vessel abnormalities his group observed after antiangiogenic treatment. The time span of normalization, the "normalization window," describes the period in which abnormal vessels either regress or normalize. In this period, the nutrient, drug, and oxygen supply is thought to be improved [77, 78] . Eventually, all tumors show resistance, after which vessels become abnormal again. The time span of this window is unknown for most drugs and, in addition to drug characteristics, may depend on the tumor type and possibly on individual tumor and patient characteristics. Because of these time-dependent tumor changes, it seems extremely important to know when to scan in order to adequately measure treatment effect.
In most protocols, time to response evaluation is based on CT response protocols instead of considerations of tumor biology. This might be one of the reasons why H 2 15 O-PET and DCE-MRI failed to demonstrate a correlation with outcome in some trials.
The reported normalization windows after treatment with VEGF TKIs or MAbs have been heterogeneous [79, 80] , which makes designing future trials difficult but challenging. Serial measurements can aid in the definition of this time window for new drugs [79] . Therefore, if financially and logistically possible, serial PET and MRI measurements should be planned for new drug trials in order to assess the best time point for response monitoring after antiangiogenic treatment. Although most patients in such trials have a limited life expectancy, this strategy can result in a high cumulative radiation dose, especially with combined PET-CT scanners.
METHODOLOGICAL CONSIDERATIONS-FACTORS INFLUENCING QUANTITATIVE MEASUREMENTS OF TUMOR PERFUSION AND PERMEABILITY
AIF Definition
Independently of the parameter used, several considerations have to be made about the ROI and AIF. The latter describes the concentration of MRI contrast or PET tracer in plasma over time, which has a great influence on measurements of (semi)quantitative parameters. It is generally accepted that the AIF varies between patients and between visits within each patient because of variations in cardiac output, renal function, and vascular tone. In principle, the AIF should be accurately measured for each scan. With PET, accurate measurement of the AIF can be obtained by arterial blood sampling with an online system, measuring arterial radioactivity concentration independently of tumor site. Because arterial sampling is invasive, an image-derived AIF may be more convenient. However, in many cases it is not possible to measure an image-derived AIF because of the absence of a suitable artery within the imaging field of view.
With MRI, image-derived measurement of the AIF is the only option, because measurement of the contrast agent concentration by arterial sampling is not possible. AIF measurements have shown that DCE-MRI reproducibility is worse with suboptimal AIF definition than with using a standardized AIF [49, 81] . In addition, the relation between tracer concentration and signal intensity becomes progressively nonlinear with increasing tracer concentration. This is especially the case in the feeding artery during the first passage of the administered bolus. Therefore, it has been proposed that the AIF should be measured with a small prebolus, and then the true AIF for the main bolus can be reconstructed from this [82] . Several other methods have been developed to meet this problem. Most of them are based on reference region models or a functional form of a population-derived AIF [81, 83] . Whichever technique is being used, it has a great impact on the results.
Tissue ROI Definition
The tissue ROI should be a well-defined part of the tumor, consistent throughout follow-up and preferably throughout the whole study to avoid sampling errors. This could be the entire tumor or a subregion. ROI can be defined on CT, MRI, PET emission, or PET transmission images. DCE-MRI obviously uses the high-resolution MR images, but PET has no well-defined anatomic landmarks available. CT can be used, but coregistration incorporates spatial error. Integrated PET-CT overcomes much of this problem, although respiratory motion still challenges accurate coregistration in the thorax and upper abdomen. Definition of anatomic ROIs using CT and MRI has its own disadvantages. Metabolically inactive areas (reflecting necrosis) are difficult to identify and might be incorporated, causing underestimation of the perfusion in viable tumor tissue. In addition, atelectasis and adjacent infectious consolidation complicate ROI definition.
With PET, ROI can be defined either on the H 2
15
O image or on a subsequently performed PET scan with a tissueaccumulating tracer. Because of the limited spatial resolution of PET and the "noisy" data produced by a diffusible tracer like H 2 15 O, ROI definition on an H 2 15 O-PET image is difficult (Fig. 3A) . Peritumoral areas of high flow (resulting from infection or adjacent large vessels) and small or highly irregular tumors complicate delineation. Parametric images, depicting flow instead of radioactivity concentration, show better tumor-to-background contrast [19] , but are still in need of improvement (Figs. 3B and 4) . In the case of heterogeneity, areas of low or absent flow are not accounted for (not visible) and only perfused areas are selected. Therefore, the ROIs defined on parametric images probably do not reflect the true tumor mass. Adding a tissue-accumulating tracer (allowing for better tumor-tobackground contrast, e.g., 18 FDG or 18 FLT) to the scan protocol creates the opportunity to define an ROI reflecting metabolically active tissue, which can then be copied to the perfusion image (Fig. 3) .
Preferably, a 3D ROI is constructed to ensure all tumor tissue is incorporated. When 2D regions are used, it is recommended to have a minimum of three sections through the tumor in order to account for spatial heterogeneity within a lesion [84] . ROI definition is not easy and straightforward, but should be based on the desired information and knowledge of treatment effects, and, most importantly, it should be performed in a standardized, reproducible manner [85] .
Organ and Tumor Position
Quantification of tumor perfusion is more complicated in the lung and upper abdominal lesions. In the liver, AIF definition is difficult because of the dual hepatic blood supply (portal vein and hepatic artery). The hepatic artery accounts for the greatest part of the blood supply to liver tumors, but the portal vein contributes to a small amount in small metastases and at the surface of large metastases [86 -89] . A model including the dual hepatic blood supply, addressing these issues, has been suggested [90, 91] .
Tumor motion influences delineation and quantification. Thoracic lesions at the base of the lung and close to the thoracic wall, as well as upper abdominal lesions, are most vulnerable to respiratory motion [92] . A dynamic DCE-MRI sequence can be performed within a single breathhold, thereby avoiding substantial motion error. PET, with its lower temporal resolution, is especially affected. Pulmonary gated PET, using only the data required during a certain phase of the respiratory motion cycle, is a promising tool to compensate for this type of error [93, 94] , although difficult to implement for dynamic H 2 15 O scans because of limited count rates.
Spatial and Temporal Resolution
Heterogeneity occurs at the microscopic level. DCE-MRI with its high spatial resolution, typically 1.5 ϫ 1.5 mm inplane and 10 mm through-plane, offers detailed pictures, whereas PET has a spatial resolution of approximately 6 mm, resulting in an averaged perfusion picture [95] . MRI 640 Measuring Tumor Blood Flow with H 2 15 O-PET and DCE-MRI also has better temporal resolution, which is on the order of 0.1 seconds for a 2D acquisition and 1 second for a 3D acquisition. This ensures that the upslope of the contrast enhancement can be measured with adequate temporal resolution, mostly within one breathhold. This allows for detailed heterogeneity analyses that might add to perfusion measures. Tumor vasculature is highly heterogeneous throughout lesions, both in place and time. Microvascular blood flow fluctuates markedly within seconds, even without treatment [96, 97] . Excellent spatial and temporal resolution only give a quick snapshot and might not be representative of the overall vascular status within a given tumor region. Therefore, it can be hypothesized that an average picture (time and place) might provide more practical information than a detailed one.
Partial Volume Effects
Partial volume effects typically occur in small lesions. This effect refers to two distinct phenomena that negatively influence quantitative measurements, image blurring and averaging signal at the voxel level [98] . Because of the finite resolution, the activity of a small source is projected as a larger but less active source (part of the signal spills out). Averaging at the voxel level occurs with all image modalities and is explained by the fact that every image is built up by pixels (2D) or voxels (volumetric pixels, 3D). Lesion boundaries do not conform themselves to this tight framework and thus voxels can exhibit both tumor and adjacent tissue, resulting in an over-or underestimation of the true pixel/voxel activity. In this way, spill in can also be explained. Nearby large vessels, obviously with high blood flow, can cause spill in of activity that can be accounted for in compartment models (equation 4). In a similar way, hypoperfused lesions surrounded by physiologically highly perfused tissue (e.g., liver or spleen) are also affected.
Response Definition in Clinical Trials
Response evaluation is usually done by calculating the percentage change between baseline and post-treatment values. This delta function substantially depends on the value of the divisor. With a small divisor, a small difference results in an unrealistic response rate. At the other end of the spectrum, a response could be missed because of a relatively large divisor. Thus, simply calculating the percentage change might not be useful for very small or large tumors. Reproducibility studies can shed light on this subject [99] . Quantification is highly dependent on both hardware and software. Image resolution, reconstruction methods, ROI strategy, and quality control (i.e., calibration) all account for fluctuations in results. Differences of up to 40% are described in the literature for standardized uptake values (SUVs) with 18 FDG-PET [100] . SUV measurements, however, require crosscalibration of a dose calibrator and the PET scanner, whereas flow measurements using H 2
15
O do not, removing uncertainties resulting from calibration errors in the case of flow studies. In general, most errors can be overcome when only one scanner is used, together with uniform reconstruction methods and data analysis. However, today most clinical studies are multicenter designed. If absolute values are necessary for within-study evaluation and when general recommendations for cutoff values are desired, standardization is required. Until that time, it is recommended that at least each patient be scanned on the same scanner pre-and post-treatment with equal methods of scan acquisition, data reconstruction, and analysis. In this way, the proportional change in flow values can be used safely. 
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